Danaher (NYSE:DHR) Raised to “Buy” at Bank of America

Bank of America upgraded shares of Danaher (NYSE:DHR) from a neutral rating to a buy rating in a research note published on Friday, Marketbeat.com reports. Bank of America currently has $290.00 price objective on the conglomerate’s stock.

Other equities research analysts have also recently issued research reports about the company. Robert W. Baird decreased their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. UBS Group decreased their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. TD Cowen raised their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Finally, Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.95.

Danaher Trading Up 0.2 %

DHR opened at $234.89 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company’s 50 day moving average price is $246.92 and its two-hundred day moving average price is $257.43. The firm has a market capitalization of $169.66 billion, a price-to-earnings ratio of 44.83, a PEG ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. As a group, research analysts predict that Danaher will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s dividend payout ratio is 20.61%.

Institutional Trading of Danaher

Hedge funds and other institutional investors have recently bought and sold shares of the business. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the 2nd quarter valued at about $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter valued at about $25,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the 3rd quarter worth about $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter worth approximately $50,000. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.